Moderna (XTER:0QF) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:0QF Moderna Inc XTER:0QF
67 GF Score
Price €60.24
GF Value €19.30
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Moderna Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

XTER:0QF
67GF Score
Moderna Inc XTER:0QF
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moderna (XTER:0QF) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €60.24 is trading 212.1% above its estimated GF Value™ of €19.30. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for XTER:0QF:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €19.30 vs. price of €60.24 (212.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the XTER:0QF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
67GF Score

Get the complete analysis for XTER:0QF

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.24
Price
€19.30
GF Value